VTRS · 10-Q · 2026Q2 · Full report
Regulatory Risk
Viatris Inc · 2026-08-06 · Importance 47 · Surprise 60 · In source text
A February 2026 fire at Viatris’ oral solid-dose manufacturing facility in Nashik, India temporarily suspended manufacturing. After a May 2026 FDA inspection produced Form 483 observations, Viatris began a comprehensive remediation plan supported by independent third-party experts; remediation has caused intermittent disruptions even though production has resumed. The company expects resulting product-supply disruptions to reduce second-half 2026 total revenues by $100 million-$150 million. Viatris recognized $86.8 million of charges in the first six months of 2026, primarily for damaged inventory and fixed assets and incremental manufacturing variances.
Key facts
- Following an FDA inspection at the Indore facility in 2024, the FDA issued a warning letter and an import alert related to this facility, and the import alert affects 11 products that will no longer be accepted into the U.S. until the warning letter is lifted. source
- In May 2026, the FDA inspected the Nashik facility and issued Form 483 observations, and the Company responded and initiated a comprehensive remediation plan. source
- The Company anticipates that the Indore facility will be ready for reinspection in 2026. source
Impact estimates
| metric | direction | stage | expected | basis |
|---|---|---|---|---|
| revenue | negative | probable | — | Following an FDA inspection at the Indore facility in 2024, the FDA issued a warning letter and an import alert related to this facility,… |
| revenue | negative | probable | — | In May 2026, the FDA inspected the Nashik facility and issued Form 483 observations, and the Company responded and initiated a… |
| operating_income | positive | probable | — | The Company anticipates that the Indore facility will be ready for reinspection in 2026. |